safety profile
AbbVie’s Rinvoq Achieves Second Phase 3 Win in Alopecia Areata Trials
AbbVie; Rinvoq; upadacitinib; alopecia areata; Phase 3 clinical trial; hair regrowth; SALT score; eyebrows; eyelashes; safety profile
Novartis plans global filings after ianalumab hits primary endpoints in two Phase 3 Sjögren’s disease trials
Novartis; ianalumab; BAFF‑R; B-cell depletion; Sjögren’s disease; NEPTUNUS-1; NEPTUNUS-2; ESSDAI; Phase 3; regulatory filings; first targeted treatment; safety profile
Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares
Assembly Bio; Phase 1b trial; ABI-5366; herpes simplex virus (HSV-2); viral shedding reduction; genital lesion reduction; safety profile; Gilead Sciences; collaboration; stock purchase
ImmuneOnco and Instil Bio’s PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial
ImmuneOnco; Instil Bio; IMM2510/AXN-2510; PD-L1xVEGF bispecific antibody; NSCLC; Phase 2 clinical trial; response rate; safety profile; chemotherapy combination; lung cancer
Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment
Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile
LB-102: Promising Phase 2 Results Revive Benzamide Antipsychotics for Schizophrenia Treatment in the US
LB-102, schizophrenia, benzamide antipsychotics, Phase 2 trial, PANSS scores, safety profile, once-daily dosing
Protara Therapeutics Sees Significant Stock Surge Following Positive Phase 2 Trial Results for TARA-002 in Bladder Cancer
Protara Therapeutics, TARA-002, bladder cancer, NMIBC, Phase 2 trial, complete response rate, safety profile
Gilead and Arcellx Present Promising CAR-T Therapy Data for Advanced Multiple Myeloma, Highlighting Safety and Efficacy Against Carvykti
Gilead, Arcellx, CAR-T therapy, multiple myeloma, anito-cel, Carvykti, ASH 2024, safety profile, efficacy, relapsed/refractory multiple myeloma
Gilead and Arcellx Highlight Promising CAR T Therapy for Multiple Myeloma with Enhanced Safety Profile
CAR T therapy, multiple myeloma, anito-cel, Gilead, Arcellx, safety profile, efficacy, clinical trials
Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership
Exsilio Therapeutics, mRNA, genomic medicines, Tal Zaks, gene therapy, gene editing, lipid nanoparticle delivery, redosing, safety profile, gene therapy approval